Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Protein Kinase Inhibitors 1 | Protein Kinase Inhibitors 1 is a HIPK2 inhibitor with IC50 of 74 nM and Kd of 9.5 nM. Group: Pharmaceutical. Alternative Names: 2,4-Thiazolidinedione, 5-[[1,2-dihydro-2-oxo-6'-(1-piperazinyl)[3,3'-bipyridin]-5-yl]methylene]-; 5-((2-oxo-6'-(piperazin-1-yl)-1,2-dihydro-[3,3'-bipyridin]-5-yl)methylene)thiazolidine-2,4-dione; 5-[[1,2-Dihydro-2-oxo-6'-(1-piperazinyl)[3,3'-bipyridin]-5-yl]methylene]-2,4-thiazolidinedione. CAS No. 1365986-44-2. Pack Sizes: 20 mg. Product ID: B0084-284772. Molecular formula: C18H17N5O3S. Mole weight: 383.43. Custom synthesis is available. Send your inquiries for more information. |  London |
| AG 126 | Tyrphostins are protein tyrosine kinase inhibitors developed to inhibit cell growth through blocking the activity of certain GFRK (growth factor receptor kinases). AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 μM. It also inhibits the production of TNF-α (tumor necrosis factor-α), attenuating signaling through NF-κB, the induced expression of COX-2 and iNOS, and the inflammatory response in animal models. AG 126 is a poor inhibitor of epidermal GFRK with IC50 of 450 μM and platelet-derived GFRK with IC50 > 100 μM. AG 126 may represent a new approach for the therapy of inflammation. Uses: Anti- inflammation. Group: Pharmaceutical. Alternative Names: AG126; AG-126; Tyrphostin AG 126; UNII-7YA4AMD1JC; Tyrphostin A 10; alpha-Cyano-(3-hydroxy-4-nitro)cinnamonitrile. CAS No. 118409-62-4. Pack Sizes: 100 mg. Product ID: B1370-195904. Molecular formula: C10H5N3O3. Mole weight: 215.16. Custom synthesis is available. Send your inquiries for more information. | London |
| AVL-292 | AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL-292 targets and covalently binds to BTK, thereby preventing its activity. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: CC-292; CC292; CC 292; AVL292; AVL 292; spebrutinib. CAS No. 1202757-89-8. Pack Sizes: 1 g. Product ID: B2693-462475. Molecular formula: C22H22FN5O3. Mole weight: 423.44. Custom synthesis is available. Send your inquiries for more information. | London |
| Axitinib | Axitinib (AG013736) is a tyrosine kinase inhibitor developed by Pfizer. Axitinib is a tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ (IC50 = 1.2, 0.25, 0.29, 1.7, and 1.6 nM, respectively). It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: AG 013736; N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide; Inlyta. CAS No. 319460-85-0. Pack Sizes: 5 g. Product ID: NP3631. Molecular formula: C22H18N4OS. Mole weight: 386.5. Custom synthesis is available. Send your inquiries for more information. | London |
| CL-387785 | CL-387785, also known as EKI-785, is an irreversible inhibitor of EGF-receptor (EGFR) kinase activity in vivo (IC50 = 250-490 pM). CL-387785 covalently bound to EGF-R. It also specifically inhibited kinase activity of the protein (IC50 = 370+/-120 pM), blocked EGF-stimulated autophosphorylation of the receptor in cells (ic50 approximately 5 nM), inhibited cell proliferation (IC50 = 31-125 nM) primarily in a cytostatic manner in cell lines that overexpress EGF-R or c-erbB-2, and profoundly blocked the growth of a tumor that overexpresses EGF-R in nude mice (when given orally at 80 mg/kg/day for 10 days, daily). CL-387,785 is useful for studying the interaction of small molecules with EGF-R and may have clinical utility. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: CL-387785; CL 387785; CL-387,785; CL387785; EKI-785; EKI 785; EKI785. CAS No. 194423-06-8. Pack Sizes: 50 mg. Product ID: B0084-458793. Molecular formula: C18H13BrN4O. Mole weight: 381.233. Custom synthesis is available. Send your inquiries for more information. | London |
| Dorsomorphin | Dorsomorphin is a potent and selective inhibitor of AMPK (AMP-activated protein kinase) (Ki = 109 nM), induced by AICAR and metformin. It also inhibits bone morphogenetic protein (BMP) receptors including BMPR-IA (ALK3) and BMPR-IB (ALK6). Dorsomorphin can induce myocardial differentiation in mouse embryonic stem cells (mESCs). Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: 6-(4-(2-(Piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine; Compound C; AMPK Inhibitor, Compound C; BML-275. CAS No. 866405-64-3. Pack Sizes: 10 mg. Product ID: B0084-462934. Molecular formula: C24H25N5O. Mole weight: 399.49. Custom synthesis is available. Send your inquiries for more information. | London |
| Entrectinib | Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: RXDX101; RXDX 101; RXDX-101; NMS E628; NMS-E628; Entrectinib; N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide. CAS No. 1108743-60-7. Pack Sizes: 250 mg. Product ID: B0084-470812. Molecular formula: C31H34F2N6O2. Mole weight: 560.64. Custom synthesis is available. Send your inquiries for more information. | London |
| GSK 2606414 | GSK 2606414 is a potent and selective PERK inhibitor that suppresses PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small-molecule inhibitors. Group: Pharmaceutical. Alternative Names: GSK2606414; GSK-2606414; GSK 2606414; GSK PERK Inhibitor. 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone. CAS No. 1337531-36-8. Pack Sizes: 100 mg. Product ID: B0084-462365. Molecular formula: C24H20F3N5O. Mole weight: 451.453. Custom synthesis is available. Send your inquiries for more information. | London |
| JNK-IN-8 | JNK-IN-8 inhibits c-Jun phosphorylation in HeLa and A375 cells with EC50 of 486 nM and 338 nM, respectively. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: JNK-IN-8; JNK-IN 8; JNK-IN8; JNK Inhibitor XVI; c-Jun N-terminal Kinase Inhibitor XVI. CAS No. 1410880-22-6. Pack Sizes: 20 mg. Product ID: B0084-463416. Molecular formula: C29H29N7O2. Mole weight: 507.59. Custom synthesis is available. Send your inquiries for more information. | London |
| KD025 | KD025 is an orally available and selective ROCK2 inhibitor with IC50 value of 60 nM and Ki value of 41 nm, respectively. It was shown to suppress adipogenesis in human adipose-derived stem cells. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: SLx 2119; SLx2119; KD-025; 2-[3-[4-(1H-indazol-5-ylamino)quinazolin-2-yl]phenoxy]-N-propan-2-ylacetamide. CAS No. 911417-87-3. Pack Sizes: 100 mg. Product ID: B0084-460389. Molecular formula: C26H24N6O2. Mole weight: 452.51. Custom synthesis is available. Send your inquiries for more information. | London |
| Lapatinib | Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. Uses: Antineoplastic agents; protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: GW-572016; GSK-572016; GSK 572016. CAS No. 231277-92-2. Pack Sizes: 1 g. Product ID: NP3214. Molecular formula: C29H26ClFN4O4S. Mole weight: 581.06. Custom synthesis is available. Send your inquiries for more information. | London |
| Motesanib | Motesanib is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors. It also potently inhibits angiogenesis and induces regression in tumor xenografts. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(pyridin-4- ylmethyl)amino]pyridine-3-carboxamide; AMG 706; AMG706; AMG706; motesanib. CAS No. 453562-69-1. Pack Sizes: 100 mg. Product ID: B0084-069090. Molecular formula: C22H23N5O. Mole weight: 373.45. Custom synthesis is available. Send your inquiries for more information. | London |
| Motesanib Diphosphate | Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: Motesanib diphosphate; 857876-30-3; AMG-706; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); Motesanib diphosphate [USAN]; Motesanib phosphate; AMG 706 (Diphosphate); AMG 706; ; T6Q3060U91; Motesanib phosphate (JAN); Motesanib diphosphate (USAN); N-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; phosphoric acid; MOTESANIB PHOSPHATE [JAN]; 3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2). CAS No. 857876-30-3. Pack Sizes: 50 mg. Product ID: B0084-153042. Molecular formula: C22H29N5O9P2. Mole weight: 569.44. Custom synthesis is available. Send your inquiries for more information. | London |
| Nilotinib monohydrochloride monohydrate | Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. It also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). Uses: Tyrosine kinase inhibitors. Group: Pharmaceutical. Alternative Names: AMN-107; AMN 107; AMN107; Tasigna. CAS No. 923288-90-8. Pack Sizes: 100 mg. Product ID: B0084-182383. Molecular formula: C28H25ClF3N7O2. Mole weight: 583.99. Custom synthesis is available. Send your inquiries for more information. | London |
| NMS-1286937 | NMS1286937, also know as NMS-P937, is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor NMS-1286937 selectively inhibits PLK1, inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells. PLK1 inhibition may result in the inhibition of proliferation in PLK1-overexpressing tumor cells. PLK1 is a serine/threonine protein kinase crucial in the regulation of mitosis. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: PCM-075; PCM 075; PCM075; NMS1286937; NMS 1286937; NMS-1286937; NMS-P937; NMS-P-937; NMS-P 937; Onvansertib. CAS No. 1034616-18-6. Pack Sizes: 500 mg. Product ID: B1370-462742. Molecular formula: C24H27F3N8O3. Mole weight: 532.53. Custom synthesis is available. Send your inquiries for more information. | London |
| SB239063 | SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated human peripheral blood monocytes, SB 239063 inhibited interleukin-1 and tumor necrosis factor-alpha production. SB 239063 may be useful for the treatment of asthma and other inflammatory disorders. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: SB-239063; SB 239063. CAS No. 193551-21-2. Pack Sizes: 100 mg. Product ID: B2693-196670. Molecular formula: C20H21FN4O2. Mole weight: 368.412. Custom synthesis is available. Send your inquiries for more information. | London |
| WZ-4002 | WZ-4002 is an EGFR phosphorylation inhibitor with selectivity for EGFR T790M. It has a framework of pyrimidine compound which is different from other EGFR inhibitors. WZ-4002 exhibits anti-tumor activity. Uses: Protein kinase inhibitors. Group: Pharmaceutical. Alternative Names: WZ4002; N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide; WZ 4002. CAS No. 1213269-23-8. Pack Sizes: 50 mg. Product ID: B0084-286777. Molecular formula: C25H27ClN6O3. Mole weight: 494.98. Custom synthesis is available. Send your inquiries for more information. | London |
| X-396 | X-396 is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, X-396 binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: X-376; (R)-6-Amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-(4-methylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide; 3-Pyridazinecarboxamide, 6-amino-5-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((4-methyl-1-piperazinyl)carbonyl)phenyl)-; 6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-{4-[(4-methyl-1-piperazinyl)carbonyl]phenyl}-3-pyridazinecarboxamide. CAS No. 1365267-27-1. Pack Sizes: 25 mg. Product ID: B2693-462239. Molecular formula: C25H25Cl2FN6O3. Mole weight: 547.41. Custom synthesis is available. Send your inquiries for more information. | London |
| 2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide | 2-Amino-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide, is a precursor in the synthesis of Dasatinib, a protein tyrosine kinase inhibitor, and also for 2-Amino-thiazole-5-carboxylic Acid Phenylamide Derivatives, used as potent and selective anti-tumor drugs. Group: Pharmaceutical. Alternative Names: 2-Amino-N-(2-chloro-6-methylphenyl)-5-thiazolecarboxamide. CAS No. 302964-24-5. Pack Sizes: 1mg;1g;10g. Product ID: NP3528. Molecular formula: C11H10ClN3OS. Mole weight: 267.73. Custom synthesis is available. Send your inquiries for more information. | London |
| [(2S,6R)-6-{N4-Benzoylcydin-1-yl}-4-tritylmorpholin-2-yl]methyl dimethyl-phosphoramidochloridate | This product is a potent inhibitor of Abl kinases and was developed for the treatment of chronic myeloid leukemia (CML). It works by blocking the activity of the Bcr-Abl fusion protein, which drives the growth of CML cells. Clinical trials have shown promising results, with high rates of complete remission and durable responses in patients with CML who were resistant or intolerant to previous treatments. Group: Pharmaceutical. Alternative Names: PMO-BzC; Morpholino C subunit; Phosphoramidochloridic acid, N,N-dimethyl-, [(2S,6R)-6-[4-(benzoylamino)-2-oxo-1(2H)-pyrimidinyl]-4-(triphenylmethyl)-2-morpholinyl]methyl ester; [(2S,6R)-6-[4-(Benzoylamino)-2-oxo-1(2H)-pyrimidinyl]-4-(triphenylmethyl)-2-morpholinyl]methyl N,N-dimethylphosphoramidochloridate; N4-Bz protected C PMO Monomer. CAS No. 956139-21-2. Pack Sizes: 1 g. Product ID: B2706-339313. Molecular formula: C37H37ClN5O5P. Mole weight: 698.15. Custom synthesis is available. Send your inquiries for more information. | London |
| 4-Chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine | 4-Chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine is a highly potent and selective protein kinase CK1ε inhibitor. Evidence suggests that this compound exhibits strong neuroprotective and anti-tumor activity, and holds great promise as a potential treatment for Alzheimer's disease and select cancers. Its unique chemical structure and mechanism of action make it an exciting candidate for further preclinical and clinical development. Group: Pharmaceutical. Alternative Names: 4-Chloro-5H-pyrrolo[3,2-d]pyrimidin-2-ylamine; 5H-Pyrrolo[3,2-d]pyrimidin-2-amine, 4-chloro-. CAS No. 943736-58-1. Pack Sizes: 10 g. Product ID: B2699-100946. Molecular formula: C6H5ClN4. Mole weight: 168.58. Custom synthesis is available. Send your inquiries for more information. | London |
| A 1070722 | A 1070722 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor (Ki = 0.6 nM for GSK-3α and GSK-3β) with 50-fold selectivity over other protein kinases such as CDK. It decreases phosphorylation of microtubule-associated protein Tau in vitro. A 1070722 exhibits neuroprotective activity thus is identified as a therapeutic drug candidate for neurodegenerative and psychiatric disorders. Uses: Potential treatment of neurodegenerative disorders. Group: Pharmaceutical. Alternative Names: A 1070722; A1070722; A-1070722; 1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea. CAS No. 1384424-80-9. Pack Sizes: 1mg;1g;10g. Product ID: 1384424-80-9. Molecular formula: C17H13F3N4O2. Mole weight: 362.31. Custom synthesis is available. Send your inquiries for more information. | London |
| A12B4C3 | A12B4C3 is a potent and selective inhibitor of polynucleotide kinase/phosphatase (PNKP) (IC50 = 60 nM), a DNA repair enzyme. A12B4C3 is inactive to calcineurin, protein PP-1 or APTX. Group: Pharmaceutical. Alternative Names: A12B4C3; A-12-B-4-C-3; A 12 B 4 C 3; A12 B4 C3; A12-B4-C3; 4a,7a-Dihydro-2-(1-hydroxyundecyl)-1-[(4-nitrophenyl)amino]-6-phenyl-1H-pyrrolo[3,4-b]pyridine-5,7(2H,6H)-dione. CAS No. 1005129-80-5. Pack Sizes: 1mg;1g;10g. Product ID: 1005129-80-5. Molecular formula: C30H38N4O5. Mole weight: 534.65. Custom synthesis is available. Send your inquiries for more information. | London |
| Acteoside | Verbascoside is a bioactive polyphenol from olive oil mill wastewater with known antioxidant activity, which is a protein kinase C inhibitor. Uses: Antineoplastic; antimetastatic;antimicrobial activity. Group: Pharmaceutical. Alternative Names: Verbascoside; Kusaginin; β-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-α-L-mannopyranosyl)-, 4-[3-(3,4-dihydroxyphenyl)-2-propenoate]. (E)-; (3,4-Dihydroxyphenyl)ethyl O-α-rhamnopyranosyl(1→3)-4-O-caffeoyl-β-D glucopyranoside; Acteroside; Distinctive Active Powder SL Special; Distinctive Phytostem Lilac; NSC 603831; O'''-Desarabinosyllavandulifolioside A; Russetinol; Stereospermin; TJC 160; trans-Acteoside; trans-Verbascoside. CAS No. 61276-17-3. Pack Sizes: 100 mg. Product ID: NP5345. Molecular formula: C29H36O15. Mole weight: 624.59. Custom synthesis is available. Send your inquiries for more information. | London |
| Afuresertib | Afuresertib, also known as GSK2110183, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2110183 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Group: Pharmaceutical. Alternative Names: GSK-2110183; GSK 2110183; GSK2110183; GSK-2110183B; GSK 2110183B; GSK2110183B. CAS No. 1047644-62-1. Pack Sizes: 50 mg. Product ID: B1370-109132. Molecular formula: C18H17Cl2FN4OS. Mole weight: 427.32. Custom synthesis is available. Send your inquiries for more information. | London |
| Alisertib | MLN8237 is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Group: Pharmaceutical. Alternative Names: MLN8237; MLN-8237; MLN 8237; alisertib. Benzoic acid, 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-. CAS No. 1028486-01-2. Pack Sizes: 100 mg. Product ID: B2693-336876. Molecular formula: C27H20ClFN4O4. Mole weight: 518.9. Custom synthesis is available. Send your inquiries for more information. | London |
| Alpelisib | Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BYL719 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Group: Pharmaceutical. Alternative Names: BYL-719; BYL719; BYL 719; Alpelisib. CAS No. 1217486-61-7. Pack Sizes: 100 mg. Product ID: B0084-457654. Molecular formula: C19H22F3N5O2S. Mole weight: 441.473. Custom synthesis is available. Send your inquiries for more information. | London |
| α-Amyrin | α-Amyrin is a triterpenoid that has been found in B. copallifera and has diverse biological activities. It activates the ERK and GSK-3β signaling pathways. α-Amyrin is a potential protein kinase A inhibitor. Group: Pharmaceutical. Alternative Names: Viminalol; alpha-Amyrenol; Urs-12-en-3beta-ol; (3β)-urs-12-en-3-ol. CAS No. 638-95-9. Pack Sizes: 10 mg. Product ID: B1370-147265. Molecular formula: C30H50O. Mole weight: 426.73. Custom synthesis is available. Send your inquiries for more information. | London |
| AR-A014418 | AR-A014418 is an ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK-3β), a serine/threonine protein kinase involved in multiple diseases including Alzheimer's disease and type 2 diabetes. Group: Pharmaceutical. Alternative Names: SN 4521; SN4521; SN-4521; AR-A 014418; AR-A014418; AR-A-014418; AR-AO-14418; GSK-3beta Inhibitor VIII; 1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea. CAS No. 487021-52-3. Pack Sizes: 25 mg. Product ID: B0084-258809. Molecular formula: C12H12N4O4S. Mole weight: 308.312. Custom synthesis is available. Send your inquiries for more information. | London |
| AZD-5363 | AZD-5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD-5363 binds to and inhibits all AKT isoforms. This agent may be used as monotherapy or combination therapy for a variety of human cancers. Group: Pharmaceutical. Alternative Names: AZD5363; AZD 5363; Capivasertib. CAS No. 1143532-39-1. Pack Sizes: 10 mg. Product ID: B2693-457058. Molecular formula: C21H25ClN6O2. Mole weight: 428.9152. Custom synthesis is available. Send your inquiries for more information. | London |
| Balanol | It is produced by the strain of Streptomyces sp. Tu 4128. Balanol, a fungal metabolite, is a potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA). It is an important target in oncology. Group: Pharmaceutical. Alternative Names: 4-(2-Carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic Acid (3R,4R)-Hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl Ester; (3R-trans)-Balanol; (-)-Balanol; Azepinostatin; Ophiocordin. CAS No. 63590-19-2. Pack Sizes: 1mg;1g;10g. Product ID: BBF-00627. Molecular formula: C28H26N2O10. Mole weight: 550.53. Custom synthesis is available. Send your inquiries for more information. | London |
| Brigatinib | Brigatinib, also known as AP-26113, is an orally active, potent and selective dual ALK/EGFR inhibitor. AP26113 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK; IC50 < 100 nM in Ba/F3 cells). AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. It blocks ALK activity and reduces growth in neuroblastoma cells, mouse xenograft, and Drosophila model systems harboring constitutively active ALK variants. Group: Pharmaceutical. Alternative Names: AP26113. CAS No. 1197953-54-0. Pack Sizes: 1 g. Product ID: B0084-470820. Molecular formula: C29H39ClN7O2P. Mole weight: 584.1. Custom synthesis is available. Send your inquiries for more information. | London |
| BX-795 | 3-Phosphoinositide-dependent protein kinase 1 (PDK1) is a serine-threonine kinase that phosphorylates and activates a range of other kinases, including PKB, PKA, and certain isoforms of PKC. BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, which is 140- and 1600-fold more selective than PKA and PKC. It is also a potent and relatively specific inhibitor of TBK1 with IC50 of 6 nM and IKK? with IC50 of 41 nM. Group: Pharmaceutical. Alternative Names: BX 795; BX795. CAS No. 702675-74-9. Pack Sizes: 25 mg. Product ID: B0084-194478. Molecular formula: C23H26IN7O2S. Mole weight: 591.47. Custom synthesis is available. Send your inquiries for more information. | London |
| Chelerythrine | Chelerythrine is a benzophenanthridine alkaloid extracted from the plant Greater celandine (Chelidonium majus). It is a potent, selective, and cell-permeable protein kinase C inhibitor. It is also the major active natural product found in the plant Zanthoxylum clava-herculis, exhibiting anti-bacterial activity against Staphylococcus aureus. Chelerythrine inhibits the BclXL-Bak BH3 peptide binding with IC50 of 1.5 μM and displaces Bax from BclXL. Chelerythrine triggers apoptosis and autophagy. Uses: Antibacterial agent. Group: Pharmaceutical. Alternative Names: Toddalin; cheleritrine; broussonpapyrine; Toddaline; [1,3]Benzodioxolo[5,6-c]phenanthridinium, 1,2-dimethoxy-12-methyl-; NSC646662; 1,2-Dimethoxy-N-methyl(1,3)benzodioxolo(5,6-c)phenanthridinium chloride. CAS No. 34316-15-9. Pack Sizes: 50 mg. Product ID: NP0509. Molecular formula: C21H18NO4+. Mole weight: 348.37. Custom synthesis is available. Send your inquiries for more information. | London |
| Chrysophanol | Chrysophanic acid (Chrysophanol) is a natural anthraquinone with anticancer activity in EGFR-overexpressing SNU-C5 human colon cancer cells. Chrysophanic acid preferentially blocked proliferation in SNU-C5 cells but not in other cell lines (HT7, HT29, KM12C, SW480, HCT116 and SNU-C4) with low levels of EGFR expression. Chrysophanic acid treatment in SNU-C5 cells inhibited EGF-induced phosphorylation of EGFR and suppressed activation of downstream signaling molecules, such as AKT, extracellular signal-regulated kinase (ERK) and the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (p70S6K). Chrysophanic acid (80 and 120 μm) significantly blocked cell proliferation when combined with the mTOR inhibitor, rapamycin. These findings offer the first evidence of anticancer activity for chrysophanic acid via EGFR/mTOR mediated signaling transduction pathway. Chrysophanol is a natural compound found in the roots and rhizomes of Rheum palmatum L. It can be used in cosmetics material. Uses: Anti-inflammatory. Group: Pharmaceutical. Alternative Names: 1,8-dihydroxy-3-methylanthracene-9,10-dione. CAS No. 481-74-3. Pack Sizes: 1 g. Product ID: NP0901. Molecular formula: C15H10O4. Mole weight: 254.24. Custom synthesis is available. Send your inquiries for more information. | London |
| CZ415 | CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model and exhibits excellent cell permeability. In the issue, Bergamini et al., who has identified CZ415, confirmed with its extraordinary selectivity, drug-like properties and proven efficacy in vivo, CZ415 represents an ideal molecule for the pharmacological investigation of mTOR pathophysiological role in vivo. Assessed in dose response format from HEK293T cells after treatment with CZ415: 1. inhibition of S6RP (downstream of mTORC1) phosphorylation in HEK293T: IC50 = 14.5 nM; 2. inhibition of Akt (mTORC2 substrate) phosphorylation in HEK293T: IC50 = 14.8 nM; 3. inhibition of IFNγ release in stimulated human whole blood: IC50 = 226 nM. Group: Pharmaceutical. Alternative Names: CZ415; CZ-415; CZ 415; (S)-1-(4-(7,7-dimethyl-4-(3-methylmorpholino)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)phenyl)-3-ethylurea. CAS No. 1429639-50-8. Pack Sizes: 5 mg. Product ID: B0084-474821. Molecular formula: C22H29N5O4S. Mole weight: 459.57. Custom synthesis is available. Send your inquiries for more information. | London |
| D-erythro-Sphingosine | D-erythro-Sphingosine is a natural isomer of sphingosine and acts as an inhibitor of protein kinase C and calmodulin-dependent enzymes with no effects on protein kinase A or myosin light chain kinase. It may stimulate mast cells by activation of protein kinase C. Group: Pharmaceutical. Alternative Names: Sphingosine (d18:1); sphingosine; D-Sphingosine; 4-Sphingenine; 2S, 3R(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol; (2S,3R,4E)-2-amino-1,3-octadec-4-enediolsphing-4-enine. CAS No. 123-78-4. Pack Sizes: 250 mg. Product ID: B2693-162633. Molecular formula: C18H37NO2. Mole weight: 299.49. Custom synthesis is available. Send your inquiries for more information. | London |
| Encorafenib | Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Group: Pharmaceutical. Alternative Names: LGX818; LGX-818; LGX 818; Methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate. CAS No. 1269440-17-6. Pack Sizes: 150 mg. Product ID: B0084-462563. Molecular formula: C22H27ClFN7O4S. Mole weight: 540.011. Custom synthesis is available. Send your inquiries for more information. | London |
| Enzastaurin | Enzastaurin is a protein kinase C beta inhibitor with 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden. Group: Pharmaceutical. Alternative Names: 3-(1-Methyl-1H-indol-3-yl)-4-(1-(1-(pyridin-2-ylmethyl)piperidin-4-yl)-1H-indol-3-yl)-1H-pyrrole-2,5-dione; LY-317615. CAS No. 170364-57-5. Pack Sizes: 200 mg. Product ID: B0084-085618. Molecular formula: C32H29N5O2. Mole weight: 515.617. Custom synthesis is available. Send your inquiries for more information. | London |
| ETC-1002 | ETC-1002 is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule and is activator of hepatic AMP-activated protein kinase (AMPK). It also has potent inhibitory activity against hepatic ATP-citrate lyase. Group: Pharmaceutical. Alternative Names: ESP-55016; ESP55016; ESP 55016; ETC-1002; ETC 1002; ETC1002; Bempedoate; Bempedoic acid. CAS No. 738606-46-7. Pack Sizes: 250 mg. Product ID: B0084-463320. Molecular formula: C19H36O5. Mole weight: 344.49. Custom synthesis is available. Send your inquiries for more information. | London |
| Ethyl (4-((2-(Methylcarbamoyl)pyridin-4-yl)oxy)phenyl)carbamate | An impurity of Sorafenib. Sorafenib is a small inhibitor of several tyrosine protein kinases, such as VEGFR, PDGFR and Raf family kinases, for the treatment of primary kidney cancer, advanced primary liver cancer and radioactive iodine resistant advanced thyroid carcinoma. Group: Pharmaceutical. Alternative Names: PAPE-ethyl Carbamate; Sorafenib related compound 7. CAS No. 2206827-12-3. Pack Sizes: 100 mg. Product ID: B2694-479756. Molecular formula: C16H17N3O4. Mole weight: 315.32. Custom synthesis is available. Send your inquiries for more information. | London |
| (E/Z)-Endoxifen | One of the impurities of Tamoxifen, which is an estrogen response modifier as well as protein kinase C inhibitor. Group: Pharmaceutical. Alternative Names: 4-Hydroxy-N-Desmethyl Tamoxifen; N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture); 4-[1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol. CAS No. 110025-28-0. Pack Sizes: 10 mg. Product ID: B2694-257357. Molecular formula: C25H27NO2. Mole weight: 373.5. Custom synthesis is available. Send your inquiries for more information. | London |
| Fasudil hydrochloride | Fasudil HCl, a 5-isoquinolinesulfonamide derivative, is a highly selective Rho-associated protein kinase inhibitor that might have a rate in romoting the recovery of neurological function, reducing clinical symptoms and the morbidity. Uses: Fasudil hcl, a 5-isoquinolinesulfonamide derivative, is a highly selective rho-associated protein kinase inhibitor that might have a rate in romoting the recovery of neurological function, reducing clinical symptoms and the morbidity. Group: Pharmaceutical. Alternative Names: Fasudil HCl; Eril; Fasudil (Hydrochloride); Fasudil Monohydrochloride; AT-877; HA-1077; AT 877; HA 1077; AT877; HA1077. CAS No. 105628-07-7. Pack Sizes: 1 g. Product ID: B2693-053715. Molecular formula: C14H18ClN3O2S. Mole weight: 327.83. Custom synthesis is available. Send your inquiries for more information. | London |
| Ganoderiol F | Lansiumarin C is a natural coumarin found in the branches of Clausena lansium. and found to induce senescence of cancer cell lines, it induces growth arrest of cancer cell lines HepG2, Huh7 and K562; activation of the mitogen-activated protein kinase EKR and up-regulation of cyclin-dependent kinase inhibitor p16 were found in early stages of Ganoderiol F treatment and were presumed to cause cell-cycle arrest and trigger premature senescence of HepG2 cells; suggests that the growth-arrest and senescence induction capability on cancer cells suggest anticancer potential of Ganoderiol F. It could be developed further as both anti-HIV and antimalaria.In Compared to plasmepsin I, ganoderiol-F is higher towards HIV-1 protease. Uses: Anti-inflammatory; anti-hiv. Group: Pharmaceutical. Alternative Names: 26,27-Dihydroxylanosta-7,9(11),24-trien-3-one. CAS No. 114567-47-4. Pack Sizes: 1 mg. Product ID: NP6829. Molecular formula: C30H46O3. Mole weight: 454.7. Custom synthesis is available. Send your inquiries for more information. | London |
| GDC-0994 | GDC-0994, also known as RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: GDC0994; GDC 0994; RG7842; RG-7842; RG 7842; Ravoxertinib. CAS No. 1453848-26-4. Pack Sizes: 50 mg. Product ID: B2693-462528. Molecular formula: C21H18ClFN6O2. Mole weight: 440.863. Custom synthesis is available. Send your inquiries for more information. | London |
| Genistein | Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. Genistein is developed to be an antitumor agent. Genistein has antioxidant effect, it can be used in cosmetics material. It is a plant polyphenol that can inhibit tyrosinase, block melanin synthesis, reduce skin pigment intensity, absorb UV, prevent photoaging, reduce sun damage and age spot formation, and whiten and lighten spots. It also has the anti-glycation and antibacterial effect, can effectively improve skin tone and skin texture, prevent the generation of age spots, remove red bloodlines, and improve skin blood microcirculation. Uses: Antitumor agent. Group: Pharmaceutical. Alternative Names: 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Baichanin A; Bonistein; 4',5,7-Trihydroxyisoflavone; GeniVida; Genisteol; NSC 36586; Prunetol; Sophoricol; Differenol A. CAS No. 446-72-0. Pack Sizes: 5 g. Product ID: BBF-01840. Molecular formula: C15H10O5. Mole weight: 270.24. Custom synthesis is available. Send your inquiries for more information. | London |
| Ginsenoside F4 | Ginsenoside F4 is extracted from the root of Panax ginseng C. A. Mey. It has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis. It was found to strongly inhibit activation of p38 mitogen-activated protein kinase in signal transduction pathways. Group: Pharmaceutical. Alternative Names: Ginsenoside Rg6; (20E)-Ginsenoside F4. CAS No. 181225-33-2. Pack Sizes: 10 mg. Product ID: B0005-454183. Molecular formula: C42H70O12. Mole weight: 767. Custom synthesis is available. Send your inquiries for more information. | London |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Group: Pharmaceutical. Alternative Names: GSK461364; GSK 461364; GSK-461364; GSK461364A; GSK 461364A; GSK-461364A. 5-[6-[(4-Methyl-1-piperazinyl)methyl]-1h-benzimidazol-1-yl]-3-[(1r)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide. CAS No. 929095-18-1. Pack Sizes: 10 mg. Product ID: B0084-307746. Molecular formula: C27H28F3N5O2S. Mole weight: 543.609. Custom synthesis is available. Send your inquiries for more information. | London |
| Ipatasertib | Ipatasertib, also known as GDC-0068 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GDC-0068 binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: GDC-0068; GDC0068; GDC 0068; RG7440; RG-7440; RG 7440; Ipatasertib. CAS No. 1001264-89-6. Pack Sizes: 50 mg. Product ID: B2693-456282. Molecular formula: C24H32ClN5O2. Mole weight: 458. Custom synthesis is available. Send your inquiries for more information. | London |
| Ku-0063794 | KU-0063794 is an inhibitor of both mTORC1 and mTORC2 with an IC50 of approximately 10 nM, but does not suppress the activity of 76 other protein kinases or seven lipid kinases, including Class 1 PI3Ks (phosphoinositide 3-kinases) at 1000-fold higher concentrations. KU-0063794 is cell permeant, suppresses activation and hydrophobic motif phosphorylation of Akt, S6K and SGK, but not RSK (ribosomal S6 kinase), an AGC kinase not regulated by mTOR. It also inhibited phosphorylation of the T-loop Thr308 residue of Akt phosphorylated by PDK1 (3-phosphoinositide-dependent protein kinase-1). It does not affect Thr308 phosphorylation in fibroblasts lacking essential mTORC2 subunits. KU-0063794 also suppressed cell growth and induced a G1-cell-cycle arrest. KU-0063794 will be useful in delineating the physiological roles of mTOR and may have utility in treatment of cancers in which this pathway is inappropriately activated. Uses: Differentiation. Group: Pharmaceutical. Alternative Names: KU0063794; KU-0063794; KU 0063794; Ku0063794; Ku 0063794; Ku-0063794; KU63794; KU 63794; KU-63794; [5-[2-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-4-morpholin-4-ylpyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol. CAS No. 938440-64-3. Pack Sizes: 100 mg. Product ID: B0084-100850. Molecular formula: C25H31N5O4. Mole weight: 465.554. Custom synthesis is available. Send your inquiries for more information. | London |
| LDS 867 | LDS 867 is a potent and selective protein kinase D (PKD) inhibitor used in the biomedical industry for research on cancer treatment. It effectively inhibits PKD and displays anticancer activity against a range of malignancies, including breast and pancreatic cancers. LDS 867 is a valuable tool in the study of PKD signaling pathways and potential therapeutic strategies for various diseases. Group: Pharmaceutical. Alternative Names: Benzothiazolium, 2-[[4-[4-[4-(dimethylamino)phenyl]-1,3-butadienyl]-2H-1-benzopyran-2-ylidene]methyl]-3-ethyl perchlorate. CAS No. 106025-71-2. Pack Sizes: 250 mg. Product ID: B2708-285552. Molecular formula: C31H29N2OS?ClO4. Mole weight: 577.1. Custom synthesis is available. Send your inquiries for more information. | London |
| LY2606368 | LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. Group: Pharmaceutical. Alternative Names: LY-2606368; LY 2606368. CAS No. 1234015-52-1. Pack Sizes: 10 mg. Product ID: B0084-462722. Molecular formula: C18H19N7O2. Mole weight: 365.397. Custom synthesis is available. Send your inquiries for more information. | London |
| Masitinib | Masitinib is an orally bioavailable and multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Group: Pharmaceutical. Alternative Names: AB-1010; AB 1010; AB1010; Masitinib. Brand name: Kinavet; Masivet. CAS No. 790299-79-5. Pack Sizes: 250 mg. Product ID: B0084-077384. Molecular formula: C28H30N6OS. Mole weight: 498.649. Custom synthesis is available. Send your inquiries for more information. | London |
| Midostaurin | Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus. Group: Pharmaceutical. Alternative Names: PKC412; PKC-412; PKC 412; PKC412A; PKC-412A; PKC 412A; CGP41251; CGP 41251; CGP-41251; Benzoylstaurosporine; 4'-N-Benzoylstaurosporine. CAS No. 120685-11-2. Pack Sizes: 20 mg. Product ID: BBF-05737. Molecular formula: C35H30N4O4. Mole weight: 570.65. Custom synthesis is available. Send your inquiries for more information. | London |
| Mubritinib | Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials (may be discontinued since 2008). Mubritinib(TAK 165) is a potent EGFR, HER2 and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 μM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Mubritinib(TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib(TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo. Group: Pharmaceutical. Alternative Names: Mubritinib; TAK165; TAK-165; TAK-165. CAS No. 366017-09-6. Pack Sizes: 50 mg. Product ID: B0084-067201. Molecular formula: C25H23F3N4O2. Mole weight: 468.48. Custom synthesis is available. Send your inquiries for more information. | London |
| N-benzyl-9Z,12Z,15Z-octadecatrienamide | Utilized in the realm of biomedical study as an inhibitor of protein kinase, the synthetically derived N-benzyl-9Z,12Z,15Z-octadecatrienamide displays potent efficacy in quelling the proliferation of human cancer cells, thereby evidencing its likelihood as a front-runner in the development of cancer therapy. Group: Pharmaceutical. Alternative Names: N-benzyllinolenamide. CAS No. 883715-18-2. Pack Sizes: 5 mg. Product ID: NP0191. Molecular formula: C25H37NO. Mole weight: 367.6. Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyltamoxifen | N-Desmethyltamoxifen is a metabolite of tamoxifen, which is an estrogen response modifier as well as protein kinase C inhibitor. Group: Pharmaceutical. Alternative Names: Desmethyltamoxifen; Tamoxifen EP Impurity F; 2-[4-[(Z)-1,2-Diphenylbut-1-en-1-yl]phenoxy]-N-methylethan-1-amine; N-Demethyltamoxifen; Demethyltamoxifen; 2-[4-[(1Z)-1,2-Diphenyl-1-butenyl]phenoxy]-N-methylethanamine; (2-(4-((1Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)(methyl)amine; 2-[4-[(1Z)-1,2-Diphenyl-1-buten-1-yl]phenoxy]-N-methylethanamine; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N-methylethylamine; Tamoxifen Citrate EP Impurity F; Tamoxifen Citrate Impurity F; Tamoxifen Impurity F. CAS No. 31750-48-8. Pack Sizes: 1 g. Product ID: B1370-107540. Molecular formula: C25H27NO. Mole weight: 357.49. Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyl Tamoxifen HCl | One of the impurities of Tamoxifen, which is an estrogen response modifier as well as protein kinase C inhibitor. Group: Pharmaceutical. Alternative Names: (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N-methylethanamine Hydrochloride; N-Demethyltamoxifen Hydrochloride; N-Desmethyl Tamoxifen Hydrochloride. CAS No. 15917-65-4. Pack Sizes: 100 mg. Product ID: B1370-260466. Molecular formula: C25H27NO.HCl. Mole weight: 393.96. Custom synthesis is available. Send your inquiries for more information. Categories: N-DesmethylTamoxifen HCl. | London |
| Netarsudil Mesylate | Netarsudil, also known as AR-11324, is a Rho-associated protein kinase inhibitor. Netarsudil is potential useful for treating glaucoma and?/or reducing intraocular pressure. Group: Pharmaceutical. CAS No. 1422144-42-0. Pack Sizes: 10 mg. Product ID: B0084-475227. Molecular formula: C30H35N3O9S2. Mole weight: 645.742. Custom synthesis is available. Send your inquiries for more information. | London |
| OTS514 hydrochloride | The hydrochloride of OTS514. OTS514 is a potent TOPK (T-LAK cell-originated protein kinase) inhibitor (IC50 = 2.6 nM), with an inhibitory effect on small cell lung cancer (SCLC). It acts through suppressing growth of SCLC cell lines and inducing their apoptotic cell death. Group: Pharmaceutical. Alternative Names: OTS 514 hydrochloride; OTS-514 hydrochloride; OTS514 HCl. CAS No. 2319647-76-0. Pack Sizes: 10 mg. Product ID: B2693-008130. Molecular formula: C21H20N2O2S.HCl. Mole weight: 400.92. Custom synthesis is available. Send your inquiries for more information. | London |
| Palbociclib HCl | Palbociclib, also known as PD0332991, is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation. PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) (IC50=0.011 μmol/L) and Cdk6 (IC50=0.016 μmol/L), having no activity against a panel of 36 additional protein kinases. Group: Pharmaceutical. Alternative Names: PD 0332991; PD 332991; PD0332991; PD-0332991; Palbociclib hydrochloride. CAS No. 827022-32-2. Pack Sizes: 1 g. Product ID: B2693-462758. Molecular formula: C24H29N7O2.HCl. Mole weight: 483.99. Custom synthesis is available. Send your inquiries for more information. | London |
| PD0325901 | PD-0325901 is a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. Uses: Reprogramming, self-renewal. Group: Pharmaceutical. Alternative Names: PD 0325901; PD 325901. CAS No. 391210-10-9. Pack Sizes: 100 mg. Product ID: B0084-091588. Molecular formula: C16H14F3IN2O4. Mole weight: 482.198. Custom synthesis is available. Send your inquiries for more information. | London |
| PD173074 | PD173074 is a small-molecule FGFR3-selective tyrosine kinase inhibitor (TKI), as a therapeutic modality using eight UC cell lines. PD173074 suppressed cell proliferation remarkably in two cell lines, namely, UM-UC-14 and MGHU3, which expressed mutated FGFR3 protein. Cell cycle analysis revealed the growth inhibitory effect of PD173074 was associated with arrest at G(1)-S transition in a dose-depending manner. In the mouse xenograft models using subcutaneously transplanted UM-UC-14 and MGHU3, orally administered PD173074 suppressed tumor growth and induced apoptotic changes comparable with the results of our in vitro assay. These findings elucidated the effectiveness of molecular targeted approach for bladder UC harboring FGFR3 mutations and the potential utility to decrease the intravesical recurrence of nonmuscle invasive bladder UC after transurethral surgical resection. Uses: Differentiation, self-renewal. Group: Pharmaceutical. Alternative Names: PD173074; PD 173074; PD-173074. CAS No. 219580-11-7. Pack Sizes: 50 mg. Product ID: B2693-263525. Molecular formula: C28H41N7O3. Mole weight: 523.682. Custom synthesis is available. Send your inquiries for more information. | London |
| PF-562271 | PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Group: Pharmaceutical. Alternative Names: PF-562271; PF 562271; PF562271. CAS No. 717907-75-0. Pack Sizes: 50 mg. Product ID: B2693-194471. Molecular formula: C21H20F3N7O3S. Mole weight: 507.49. Custom synthesis is available. Send your inquiries for more information. | London |
| PP2 | PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM), and Src (IC50 = 100 nM). Group: Pharmaceutical. Alternative Names: PP-2; PP 2; AG 1879; AG-1879; AG1879. CAS No. 172889-27-9. Pack Sizes: 100 mg. Product ID: B2693-169928. Molecular formula: C15H16ClN5. Mole weight: 301.77. Custom synthesis is available. Send your inquiries for more information. | London |
| Radotinib-[d6] | Radotinib-[d6] is deuterium labelled Radotinib. Radotinib, also known as IY-5511, is a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Group: Pharmaceutical. Alternative Names: 4-(Methyl-d3)-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzamide-2,5,6-d3. CAS No. 2754051-83-5. Pack Sizes: 1 mg. Product ID: BLP-014895. Molecular formula: C27H15D6F3N8O. Mole weight: 536.55. Custom synthesis is available. Send your inquiries for more information. | London |
| Ribociclib | Ribociclib, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation. Group: Pharmaceutical. Alternative Names: LEE011; LEE 011; LEE-011; Kisqali. CAS No. 1211441-98-3. Pack Sizes: 200 mg. Product ID: B0084-462559. Molecular formula: C23H30N8O. Mole weight: 434.55. Custom synthesis is available. Send your inquiries for more information. | London |
| Rigosertib sodium | Rigosertib (ON-01910 sodium salt), a synthetic benzyl styryl sulfone analogue with potential antineoplastic activity, is a non-ATP-competitive inhibitor of PLK1 (IC50=9 nM), inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Group: Pharmaceutical. Alternative Names: Glycine, N-[2-methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]-, monosodium salt (9CI); (E)-2,4,6-Trimethoxystyryl 3-[(carboxymethyl)amino]-4-methoxybenzyl sulfone sodium salt; Novonex; ON 01910 sodium; ON01910 sodium; ON-01910 sodium; ON 01910 sodium salt; Rigosertib sodium. CAS No. 1225497-78-8. Pack Sizes: 50 mg. Product ID: B0084-286621. Molecular formula: C21H24NNaO8S. Mole weight: 473.47. Custom synthesis is available. Send your inquiries for more information. | London |
| Saracatinib | Saracatinib, also known as AZD0530, is an orally available dual-specific inhibitor of Src and Abl with anti-invasive and anti-tumor activities. Src and Abl are protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. Saracatinib binds to and inhibits these tyrosine kinases and their effects on cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival. Specifically, Saracatinib inhibits Src kinase-mediated osteoclast bone resorption. Uses: Antineoplastic agents. Group: Pharmaceutical. Alternative Names: AZD 0530; AZD-0530; AZD0530. CAS No. 379231-04-6. Pack Sizes: 100 mg. Product ID: B0084-067564. Molecular formula: C27H32ClN5O5. Mole weight: 542.03. Custom synthesis is available. Send your inquiries for more information. | London |
| Seliciclib | Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Seliciclib primarily inhibits CDK2/E, CDK2/A, CDK7 and CDK9 by competing for their ATP binding sites, leading to a disruption of cell cycle progression. In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase II-dependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemia cell differentiation protein Mcl-1. CDKs, serine/threonine kinases that play an important role in cell cycle regulation, are overexpressed in various malignancies. Mcl-1 belongs to the Bcl-2 family of antiapoptotic proteins and is a protein crucial to the survival of a range of tumor cell types. Group: Pharmaceutical. Alternative Names: R-roscovitine; Roscovitin; Roscovitine; CYC202; CYC202; CYC 202; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol. CAS No. 186692-46-6. Pack Sizes: 100 mg. Product ID: B1370-086385. Molecular formula: C19H26N6O. Mole weight: 354.44. Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
